Mark Faries

13PUBLICATIONS
52CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)MechanobiologyModels of care and place of birthPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 01, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

|Oct 30, 2025
Clinical Stage II Melanoma: Is There a "Simple Trick" to Significantly Improve Event-Free Survival?

Mark B Faries, Tina J Hieken

|Feb 11, 2025
Health-related Quality of Life and hospital costs of Finnish melanoma patients participating in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II).

Pia J Heino, Jukka Pappinen, John F Thompson

|Jun 01, 2024
Regarding sentinel lymph node biopsy in younger and older patients.

M B Faries, A Varey, D A Elashoff

|Jan 02, 2024
Sentinel lymph nodes in melanoma: necessary as ever for optimal treatment.

Mark B Faries

|Aug 14, 2023
Systemic Therapy for Melanoma: ASCO Guideline Update.

Rahul Seth, Sanjiv S Agarwala, Hans Messersmith

Pageof 3

Frequent Collaborators

3 joint publications

John F Thompson

1 joint publications

S Lo

1 joint publications

Anthony T Nguyen

1 joint publications

Michael Luu